Video

Experts Raise Awareness for Colorectal Cancer

Author(s):

Onclive Team

Today, colorectal cancer (CRC) is one of the more commonly diagnosed cancers among both men and women. Although it is more likely to be diagnosed in elderly patients, CRC is continuing to be diagnosed in younger and younger patients. In the above video from the Colorectal Cancer Awareness Month Educational Video Series by CURE Media Group, experts discuss the tools available to prevent CRC and the importance of screening. The full video can be found at http://www.curetoday.com/insights/colorectal-cancer-screening.

Related Videos
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Related Content
FDA
January 10th 2025

Abenacianine Wins FDA Fast Track Designation for Tumor Visualization in the Lung

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

FDA
January 8th 2025

Invikafusp Alfa Receives FDA Fast Track Designation for TMB-High CRC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Zolbetuximab Plus Chemotherapy in Gastric/GEJ Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 6th 2025

Zolbetuximab Plus Chemo Wins Approval in China for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

Aparna Parikh, MD
January 5th 2025

Patient Factors Drive IO Combination Selection in Unresectable HCC